Vialto Partners, a provider of tax and immigration services, has agreed to restructure its debt a little more than two years ...

Clayton, Dubilier & Rice ("CD&R" or the "Firm") today announced that Bill Galvin has been engaged as an Operating Advisor to ...

To help find and source new investments, the private investment firm adds the CEO Anixter had at the time it merged with ...

Vialto Partners, a provider of tax and immigration services, has agreed to restructure its debt a little more than two years after the company spun out of PricewaterhouseCoopers and was acquired by ...

Resideo Technologies (REZI) has disclosed a new risk, in the Share Price & Shareholder Rights category. The CD&R Stockholder, holding approximately 11% of Resideo Technologies’ total voting power as ...

New Investment to Advance Vialto's Strategic Growth Initiatives and Enable Further Innovation in Technology and Teams ...

Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Read why I think EVH stock ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

CD&R is also considering the French government’s request to keep the consumer health unit’s headquarters in France, said the people, who asked not to be identified as the information is private.

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

Under the proposed deal, CD&R would acquire a 50% controlling interest in Opella, while Sanofi would retain a substantial stake, positioning itself as a key player in the company’s future trajectory.